Pharmacogenetic Biomarkers to Predict Treatment Response in Multiple Sclerosis: Current and Future Perspectives

Multiple Sclerosis International - United States
doi 10.1155/2017/6198530
Full Text
Abstract

Available in full text

Categories
Neurology
Date
Authors
Publisher

Hindawi Limited

Related search

Future Clinical Uses of Neurophysiological Biomarkers to Predict and Monitor Treatment Response for Schizophrenia

Annals of the New York Academy of Sciences
GeneticsMolecular BiologyBiochemistryNeuroscienceHistoryPhilosophy of Science
2015English

Teriflunomide in the Treatment of Multiple Sclerosis: Current Evidence and Future Prospects

Therapeutic Advances in Neurological Disorders
NeurologyPharmacology
2014English

Novel Approaches to Detect Serum Biomarkers for Clinical Response to Interferon-Β Treatment in Multiple Sclerosis

PLoS ONE
Multidisciplinary
2010English

Biomarkers of Parkinson's Disease: Current Status and Future Perspectives

Drug Discovery Today
Drug DiscoveryPharmacology
2013English

Erratum to Amyotrophic Lateral Sclerosis: Current and Future Treatment Strategies

Drugs
Pharmacology
1996English

Real-Time Monitoring of Biomarkers: Current Status and Future Perspectives

Biochip Journal
BioengineeringElectronic EngineeringBiomedical EngineeringElectricalBiotechnology
2020English

Biomarkers in Multiple Sclerosis

2007English

Biomarkers for Multiple Sclerosis

Internal Medicine
Internal MedicineMedicine
2014English

Current and Future Perspectives on Management of Systemic Sclerosis-Associated Interstitial Lung Disease

Expert Review of Clinical Immunology
AllergyImmunology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy